MMprofiler for prognostic risk classification in multiple myeloma

Equality considerations

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others.

MMprofiler is intended for prognostic testing for all people with newly diagnosed, relapsed or refractory multiple myeloma. Multiple myeloma is more common in men: 57% of cases in the UK are in men and 43% are in women. It affects mainly people over 60 and is rare in people under 40. Most cases are diagnosed around 70 years, and the incidence rates in the UK are highest in people aged 85 to 89. Incidence rates for multiple myeloma are predicted to rise by 11% in the UK between 2014 and 2035. Multiple myeloma is around twice as common in black populations than in white and Asian populations. Incidence rates in England were similar across the most deprived quintile compared with the least. Age, sex, race, and disability are protected characteristics under the Equality Act 2010.